| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530389200 | Binds hormone, lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, glucagon, cardiodilatin, interleukin, interferon, norepinephrine, epinephrine, acetylcholine, etc.) | 21 |
| 20090306348 | Antibody Formulation - The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stabile formulation of antibodies that are prone to non-enzymatic fragmentation at the hinge region. In a further embodiment, the invention provides methods of stabilization of antibodies comprising lyophilizing an aqueous formulation of an antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. In one embodiment, the present invention provides methods of stabilization of anti-VEGFR antibodies comprising lyophilizing an aqueous formulation of an anti-VEGFR antibody. The formulations can be lyophilized to stabilize the anti-VEGFR antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. | 12-10-2009 |
| 20110054151 | COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS - Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions. | 03-03-2011 |
| 20110144312 | INTERLEUKIN 10 RECEPTOR (IL-10R) ANTIBODIES AND METHODS OF USE - The invention relates to IL-1O Receptor alpha (IL-1ORα) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IORα) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1ORα) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1ORα) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization. | 06-16-2011 |
| 20110275790 | Antibodies Against Human IL-22 and Uses Therefor - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 11-10-2011 |
| 20120016109 | ESTROGEN RECEPTORS AND METHODS OF USE - The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies. | 01-19-2012 |
| 20120116059 | Treatment For MTreatment For Multiple Sclerosis - The present invention relates to methods for the treatment and/or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and/or prophylaxis of multiple sclerosis. | 05-10-2012 |
| 20120202977 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening. | 08-09-2012 |
| 20130030159 | ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF - The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases. | 01-31-2013 |
| 20130172535 | PROCESS FOR PROTEIN EXTRACTION - The invention includes a process for extracting a target protein from | 07-04-2013 |
| 20130338344 | PROTEIN PURIFICATION METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification. | 12-19-2013 |
| 20140039164 | THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONAL ANTIBODY - Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described. | 02-06-2014 |
| 20140081003 | METHODS AND COMPOSITIONS FOR PREVENTING NORLEUCINE MISINCORPORATION INTO PROTEINS - The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein. | 03-20-2014 |
| 20140088296 | IL-18 BINDING PROTEINS - The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-1 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 03-27-2014 |
| 20140275494 | PROTEIN PURIFICATION USING DISPLACEMENT CHROMATOGRAPHY - Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein. | 09-18-2014 |
| 20140303358 | Osteogenesis Promoter - The purpose of the present invention is to provide an osteogenesis promoter for directly promoting osteogenesis by osteoblasts, and an agent for preventing and treating bone disease. The present invention is characterized in that a binding inhibitor substance of semaphorin 4D and plexin B1 is used. For the binding inhibitor substance, suitable examples include anti-semaphorin 4D antibody, anti-plexin B1 antibody, and protein comprising the extracellular domain of plexin B1. | 10-09-2014 |
| 20140343258 | NOVEL ANTI-HUMAN CTGF ANTIBODY - [Problem] An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. | 11-20-2014 |
| 20150045542 | HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME - Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies. | 02-12-2015 |
| 20150299310 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 10-22-2015 |
| 20160108084 | Purification Of Recombinantly Produced Polypeptides - Described herein is a method for separating a recombinantly produced polypeptide from host cell protein. The method includes a step of loading a clarified cell culture supernatant that includes the recombinantly produced polypeptide and the HCP onto a Protein A chromatography column and washing the Protein A chromatography column with a wash buffer comprising a fatty acid having a chain length of at least about 6 carbon atoms, or a fatty acid salt thereof to remove HCP and then recovering the recombinantly produced polypeptide. | 04-21-2016 |
| 20160108119 | PROTEIN PURIFICATION - The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step. | 04-21-2016 |
| 20160186227 | METHODS AND COMPOSITIONS FOR PREVENTING NORLEUCINE MISINCORPORATION INTO PROTEINS - The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein. | 06-30-2016 |
